Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

BACC: Protocol for Rapid Diagnosis of Myocardial Infraction

The 1-hour algorithm using high-sensitivity troponin measurement for rapid diagnosis of AMI is safe.

To carry out the BACC study (Biomarkers in Acute Cardiovascular Care) the effects of the troponin assay at 1 hour were compared to its effects after the 3 hours recommended by the ESC guidelines in 1.045 patients presenting with acute chest pain (mean age 65, 64.9% male). In addition, they analyzed a cut off value of 6 ng/L, far lower than the recommended 27 ng/L 99th percentile value for the ultrasensitive troponin assay (Elecsys; Roche Diagnostics) and the high sensitivity troponin I assay (STAT hs Tn I; Abbott Diagnostics).

The use of ultrasensitive cTn I with a ≤ 6 ng/L cutoff ruled out STEMI in 402 patients after an hour, and no differences were observed when compared to discharge at 3 hours. Moreover, compared to the 6 ng/L, the 27 ng/L cutoff resulted in a lower negative predictive value (NPV), regardless testing time (P < .005 for both) and also resulted in lower sensitivity.

An algorithm to rule out NSTEMI should include the ultrasensitive cTn I > 6 ng/L after one hour with a 12 ng/L delta compared to admission values (positive predictive value PPV 87.1%; specificity 98.0%).

These algorithms were verified against 4.009 patients from the European cohort (NPV 99.2% rule out, PPV 80.4% rule in) that also used a 1 hour algorithm, and against the Australian cohort (NPV 99.7% rule out; VPP 81.5% rule in).

During a 183 day follow up, only 3 patients died (0.79%) in the rule out < 6 ng/L group. However, 12 had died (1.73%) using the 27 ng/L cut off value (P < .05).

Westermann D.

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

GLUCO-TAVI | Can Glucocorticoids Reduce the Need for Permanent Pacemaker Implantation After TAVI?

Despite the expansion of transcatheter aortic valve implantation (TAVI) indications, cardiac conduction disturbances (CCD) and the need for permanent pacemaker implantation (PPI) remain the...

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...